ORIC Pharmaceuticals, Inc. ORIC
7.75 USD +0.09 (+1.24%)
As ofNov 19, 2026, 11:57 AM EST
7.53 Day range 7.97
7.23 52-week range 14.68
- YTD
- -5.32%
- 1 year
- -32.53%
News
benzinga.com HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $20 HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $27 to $20.
benzinga.com Wells Fargo Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $23 Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.
benzinga.com Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17 Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.
benzinga.com BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
benzinga.com ORIC Pharmaceuticals Q3 EPS $(0.44) Misses $(0.39) Estimate ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 33.33 percent decrease over losses…
globenewswire.com ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayerbenzinga.com BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…benzinga.com Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18 Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
benzinga.com ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
